Metabolism and urinary excretion of a new quinoline anticancer drug, TAS-103, in humans

Xenobiotica

Volumn 32, Issue 1, 2002, Pages 63-72

  Azuma, R ^a   Saeki, M ^a   Yamamoto, Y ^a   Hagiwara, Y ^a   Grochow, L B ^b   Donehower, R C ^c  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

^b MPI   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 [2 (DIMETHYLAMINO)ETHYLAMINO] 3 HYDROXY 7H INDENO[2,1 C]QUINOLIN 7 ONE; ANTINEOPLASTIC AGENT; DRUG METABOLITE; QUINOLINE DERIVATIVE;

ARTICLE; CASE REPORT; CLINICAL TRIAL; DRUG ANALYSIS; DRUG EXCRETION; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROLYSIS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PHASE 1 CLINICAL TRIAL; ULTRAVIOLET SPECTROSCOPY;

AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; ENZYME INHIBITORS; GLUCURONIDES; HUMANS; INDENES; INFUSIONS, INTRAVENOUS; MASS SPECTROMETRY; MOLECULAR STRUCTURE; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 0036148743     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250110085818     Document Type: Article

References (12)

1. In vitro antitumor activity of TAS-103, a novel quinoline derivative that targets topoisomerases I and II
2. Simultaneous determination of a novel anticancer drug. TAS-103, and its N-demethylated metabolite in monkey plasma by high-performance liquid chromatography using solid-phase extraction
3. Validation of liquid chromatographic and gas chromatographic methods. Applications to pharmacokinetics
4. Validation of chromatographic methods in biomedical analysis. Viewpoint and discussion
5. Studies on the formation of reactive intermediates from the antineoplastic agent N,N′-bis(2-chloroethyt)-N-nitrosourea (BCNU) in vitro and in vivo. Characterization of novel glutathione adducts by ionspray tandem mass spectrometry
6. A phase I dose escalation, safety, tolerability, and pharmacokinetic study of TAS-103 in patients with refractory solid tumors
7. Biotransformation of the naturally occurring isothiocyanate sulforaphane in the rat: Identification of phase I metabolites and glutathione conjugates
8. Characterization of conjugated metabolites of a new angiotensin II receptor antagonist, candesartan cilexetil, in rats by liquid chromatography/electrospray tandem mass spectrometry following chemical derivatization
9. The use of ultraviolet spectra and chromatographic retention data as an aid to metabolite identification
10. Combination effects of TAS-103, a novel dual topoisomerase I and II inhibitor, with other anticancer agents on human small cell lung cancer cells
11. Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II
12. Metabolism of MK-499, a class III antiarrhythmic agent, in rats and dogs